article thumbnail

Key Trends Drug Developers Need to Know to Succeed

PPD

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends.

article thumbnail

Altasciences at ARVO 2025: An Eye on the Future of Ophthalmic Drug Development by Gretchen Green

Alta Sciences

We’re already looking forward to ARVO 2026 in beautiful Denver, Colorado. Her extensive background allows her to support clients at every stage of the drug development process, from initial proof of concept to NDA-enabling studies. [1] conference locations. 1] [link] ; This blog was originally published in June 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intelligently Automating Prior Authorization to Build Consumer Trust in Healthcare

Perficient: Drug Development

Prior Authorization, In a Nutshell The CMS Prior Authorization mandate , which goes into effect on January 1, 2026, aims to reduce guesswork for healthcare consumers and the administrative burden on care teams, and to improve patient/member care by streamlining processes and enhancing the exchange of health information.

article thumbnail

Moderna COVID vaccine gets full approval for children

BioPharma Drive: Drug Pricing

The company said it expects to have an updated version of its shot available in time for the 2025-2026 respiratory disease season. New data visualizations published by BioPharma Dive capture the year-to-date funding trends for 2025, which so far include a pullback in financings for cancer drug developers. Kennedy Jr.

Vaccine 226
article thumbnail

The Sun Has Started to Set on the Rare Pediatric Disease Priority Review Voucher Program – But It Can Still be Saved

FDA Law Blog: Drug Discovery

This means that, at the current moment, FDA cannot award any priority review vouchers for rare pediatric disease product applications unless it is for a drug that was designated as a drug for a rare pediatric disease not later than December 20, 2024, and such application is approved not later than September 30, 2026.

Disease 59
article thumbnail

Organon drug for endometriosis falls short in mid-stage study

BioPharma Drive: Drug Pricing

Chief Executive Kevin Ali called the drug a “multibillion dollar opportunity” during the J.P. The company had hoped to kick off Phase 3 research in 2026 and launch the medicine around 2029. Organon acquired the drug in its purchase of Forendo Pharma in 2021. Morgan Healthcare Conference in January.

article thumbnail

FDA Appears to Be Granting Zombie Rare Pediatric Disease Designations Waiting for the Rare Pediatric Disease Priority Review Voucher Program to be Revived

FDA Law Blog: Drug Discovery

However, as we suggested in a recent blog post , the statute did not actually provide any limitations on FDAs authority to grant rare pediatric disease designations , only its authority to grant vouchers.

Disease 59